153
Participants
Start Date
June 30, 2016
Primary Completion Date
June 30, 2022
Study Completion Date
December 31, 2026
Iomab-B
Conventional Care
HCT
Weill Cornell Medicine, New York
Memorial Sloan Kettering Cancer Center, New York
Stony Brook University, Stony Brook
Roswell Park Cancer Institute, Buffalo
Georgetown University Medical Center, Washington D.C.
University of North Carolina Hospital, Chapel Hill
Mayo Clinic, Jacksonville
The Ohio State University Comprehensive Cancer Center, Columbus
University Hospital of Cleveland Seidman Cancer Center, Cleveland
University of Iowa, Iowa City
Medical College of Wisconsin, Milwaukee
Mayo Clinic, Rochester
Loyola University Medical Center, Maywood
Washington University School of Medicine, St Louis
The University of Kansas Cancer Center, Westwood
University of Nebraska Medical Center, Omaha
Baylor Charles A. Sammons Cancer Center, Dallas
MD Anderson Cancer Center, Houston
Banner MD Anderson Cancer Center, Gilbert
Oregon Health & Science University, Portland
Fred Hutchinson Cancer Research Center, Seattle
Yale Cancer Center, New Haven
University of Ottawa, Ottawa
Princess Margaret Cancer Centre, Toronto
Lead Sponsor
Actinium Pharmaceuticals
INDUSTRY